Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

36.02 +0.65 (+1.82%)
Streaming Delayed Price Updated: 12:53 PM EDT, Apr 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
38 39 Next >
Preview: GlaxoSmithKline's Earnings
Via Benzinga
CureVac Shares Pop After Encouraging Update From COVID-19, Flu mRNA Vaccine Programs
Via Benzinga
The RSV Vaccine Battle Wages On With Moderna Scoring A Win Vs. Pfizer, GSK
But Moderna stock didn't move higher on the announcement. 
Via Investor's Business Daily
How Could GSK's RSV Vaccine Change its Valuation?
GSK's RSV vaccine could be a good earner for the company, according to outside analysts and its own predictions for the future. 
Via MarketBeat
Exposures Product Safety
Earnings Preview: GSK Q4 Earnings Expected To Decline
This drug developer is expected to post quarterly earnings of $0.59 per share in its upcoming report, which represents a year-over-year change of -31.4%. 
Via Talk Markets
3 Penny Stocks That Could Make You Filthy Rich
These low-priced equities could deliver enormous returns for risk-tolerant shareholders. 
Via The Motley Fool
GSK Earnings Conference Call Is Coming Up, Here's What You Need To Know
Via Benzinga
Sandoz Acquires Antifungal Agent From Astellas, Reinforcing Hospital Offering
Via Benzinga
COVID, Shmovid: This Could Be the Next Big Growth Story for Moderna Stock
Moderna could follow closely behind Pfizer and GSK in entering the lucrative RSV vaccine market. 
Via The Motley Fool
Stock Market Rally Pulls Back; Microsoft, Google Slash Jobs; Netflix, Goldman, Tesla In Focus: Weekly Review
Microsoft and Google are slashing jobs. Netflix and Tesla jumped. 
Via Investor's Business Daily
Pharmaceutical Stocks Pfizer, GSK, Moderna Come Close To Cracking A Multibillion-Dollar RSV Vaccine Market
After years of lab failures, the companies could crack open a multibillion-dollar market. 
Via Investor's Business Daily
Jim Cramer Says This Stock Up 23% In A Month Is 'A Great Speculative Buy'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Biohaven Ltd (NYSE: BHVN) is a "great speculative buy." 
Via Benzinga
Moderna Gets A 'Booster' Shot: Why Stock Is Up Nearly 7% Today
Moderna, Inc. (NASDAQ: MRNA) shares were solidly higher in premarket trading on Wednesday. 
Via Benzinga
Moderna Comes Swinging For Pfizer, GSK As RSV Vaccine Battle Heats Up
Moderna is stepping up to Pfizer and GSK, both of which are developing RSV vaccines. 
Via Investor's Business Daily
Week In Review: WuXi Biologics Out-Licenses Four TCE Antibodies To GSK In $1.5 Billion Pact
WuXi Biologics out-licensed global rights for up to four pre-clinical bi- & multi-specific TCE antibodies to GSK in a $1.5 billion agreement. WuXi Biologics will receive $40 million upfront and up to... 
Via Talk Markets
CureVac (CVAC) Stock Rises 25% on Positive Data for Covid-19 and Flu Vaccines
CureVac announced positive results for its mRNA-based Covid-19 and flu vaccine, which may offer tremendous relevance for CVAC stock. 
Via InvestorPlace
The Year of the Tripledemic
COVID-19 may have lost its daily news headline status, but the disease rages on with 2700 weekly deaths in the U.S. and millions of Americans chronically disabled from long-COVID, 4 million of which... 
Via TheNewswire.com
Topics Death
Exposures COVID-19 Death Product Safety
The Year of the Tripledemic
The Year of the Tripledemic 
Via News Direct
Topics Death
Exposures COVID-19 Death
What You Missed On Wall Street On Friday
In the midst of markets falling, some companies had good news, while others took a hit from analysts and a merger is still on hold. 
Via Talk Markets
GSK Looking For Under-Appreciated M&A Targets, Not Trying To Be Next Roche Or AstraZeneca
GSK plc (NYSE: GSK) chief commercial officer Luke Miels says the company is looking at M&A targets that are under-appreciated worth $1 billion-$2.5 billion and avoid getting into a 'bidding war.' 
Via Benzinga
Big Health Care Stocks to Watch in the New Year
Here are three health care stocks to watch as the New Year begins. Two have a moderate Buy rating while one is a Hold, for now. 
Via MarketBeat
7 Drug Stocks That Will Soar in 2023
These drug stocks to buy look poised to generate huge profits for investors in 2023 and in subsequent years. 
Via InvestorPlace
2 Smartest Tech Stocks to Buy in 2022 and Beyond
The tech space is still bursting with opportunities for long-term investors. 
Via The Motley Fool
Comparing With Pfizer's Vaccine, Icosavax RSV Candidate 'Could Establish Differentiation,' Analyst Says
Via Benzinga
Options Trader Betting On GSK Stock Rising Heading Into 2023
Options traders are making big bets on the upside for healthcare, particularly in shares of GSK plc (NYSE: GSK). 
Via Benzinga
Wave Life Sciences Shares Move Higher On Therapeutic Pact With GSK Targeting Genetic Disorders
Via Benzinga
Wave Life Sciences and GSK Announce Collaboration to Drive Discovery and Development of Oligonucleotide Therapeutics Focusing on Novel Genetic Targets
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
New data at ASH underscore the potential for durable, clinically important responses with momelotinib for myelofibrosis patients
From GSK plc
Via Business Wire
Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
Large-cap pharmaceuticals Pfizer and Johnson & Johnson are outperforming the broader market in the past year, particularly in the past three months. 
Via MarketBeat
France Health Body Advises Unfavorable Opinion Regarding Valneva's COVID-19 Vaccine
Via Benzinga
< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
38 39 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.